FDA-approved4,5Evidence: Smaller human trialsHormones

Desmopressin4

Also called DDAVP4,5

Key takeaway

Desmopressin is a lab-made analogue of vasopressin, the body’s antidiuretic hormone, and the active ingredient in DDAVP.4,5 The DDAVP label covers central diabetes insipidus and primary bedwetting in children. Two placebo-controlled trials in 340 children and teenagers found fewer wet nights with desmopressin.4 The label warns that desmopressin can cause low blood sodium, which can be fatal if not recognized, and says it must not be used by people with low blood sodium or moderate to severe kidney impairment.4

Desmopressin at a glance

What it isA synthetic analogue of the pituitary hormone arginine vasopressin with stronger antidiuretic and weaker blood-pressure effects, according to the DDAVP label.4
FDA statusFDA-approved. Drugs@FDA lists DDAVP, NDA 019955, with an original approval date of September 6, 1995. The cited label has no boxed warning.4,5
Human evidenceTwo randomized, placebo-controlled trials in 340 children and teenagers with bedwetting, and long-term studies in diabetes insipidus, described in the label.4
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is desmopressin?

Desmopressin is a synthetic version of arginine vasopressin, the pituitary hormone that helps the kidneys hold on to water, with two chemical changes. The label describes it as 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin.4

In the United States it is the active ingredient of DDAVP, approved under NDA 019955, according to Drugs@FDA.5

How does desmopressin work?

Like natural vasopressin, desmopressin acts on the kidneys to reduce urine output and concentrate urine. The label states that its structural changes give it less effect on blood pressure and smooth muscle than vasopressin, relative to its antidiuretic effect.4

What do human studies show?

The label describes two double-blind, randomized, placebo-controlled trials in 340 patients aged 5 to 17 with primary bedwetting. After two weeks, wet nights fell by 10% with placebo and by 27% to 40% with desmopressin.4

In four long-term studies of DDAVP in 46 patients with diabetes insipidus, followed for 12 to 44 months, the label reports no loss of effect and no rise in blood pressure.4

ClinicalTrials.gov also lists desmopressin trials outside the DDAVP label, such as a completed Phase 3 trial in nocturia (NCT01223937) and Phase 3 trials in low blood sodium (NCT06020495) and bleeding risk with kidney disease and surgery (NCT06337838) listed as recruiting in 2026 records.1,2,3

What the evidence base contains

  • Controlled human trial Two double-blind, randomized, placebo-controlled trials in 340 patients aged 5 to 17 with primary nocturnal enuresis, pooled in the label.4
  • Small, short, or incompletely reported human study Four long-term studies in which 46 patients with central diabetes insipidus took DDAVP for 12 to 44 months, described in the label.4

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is desmopressin FDA-approved?

Yes. Drugs@FDA lists DDAVP, application NDA 019955, with an original approval date of September 6, 1995.5

The DDAVP label cited here (DailyMed SPL version 7, published December 10, 2025) states that it is indicated as antidiuretic replacement therapy in central diabetes insipidus and for primary nocturnal enuresis, and that it is ineffective in nephrogenic diabetes insipidus.4

The label has no boxed warning. It warns that desmopressin may lead to water intoxication and low blood sodium, which can be fatal, and that it is contraindicated in people with low blood sodium or moderate to severe kidney impairment.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Desmopressin is not among them.6,7

Timeline

  1. FDA approves the DDAVP application cited here, NDA 019955, according to Drugs@FDA.5
  2. DailyMed publishes the DDAVP label version cited on this page.4

What is still unknown?

How it works in older adults: the label states that its clinical studies did not include enough people aged 65 and over to tell whether they respond differently.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Desmopressin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Desmopressin are a bounded selection, not every registration or paper about Desmopressin. For the years before Desmopressin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Desmopressin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Desmopressin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as DDAVP for diabetes insipidus and bedwetting. Two randomized, placebo-controlled trials in 340 children and teenagers described in the label found fewer wet nights with desmopressin. The label warns of low blood sodium, which can be fatal.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Desmopressin?

FDA-approved as DDAVP for diabetes insipidus and bedwetting. Two randomized, placebo-controlled trials in 340 children and teenagers described in the label found fewer wet nights with desmopressin. The label warns of low blood sodium, which can be fatal.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
29
Drugs@FDA applications
38

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Clinical trials · added November 16, 2026

    ClinicalTrials.gov record NCT06020495↗Source date October 30, 2026
  2. Literature metadata · added November 16, 2026

    Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis.↗Source date October 29, 2026
  3. Literature metadata · added November 16, 2026

    Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis.↗Source date October 12, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Desmopressin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

101Selected dated records
105Connected citations
29Populated source years1978–2026
3/4Record lanes present

Registered human studies

Trial composition

24 of 25 selected trial records include at least one phase value; 25 of 25 include a status value in the retained structured contract.

PhasesPhase 3 10Phase 4 7Phase 2 4Phase 1 3
Status at observationCompleted 21Recruiting 4

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Review 12Meta-Analysis 8Systematic Review 8Research Support, Non-U.S. Gov't 5Randomized Controlled Trial 4Multicenter Study 1Network Meta-Analysis 1Research Support, U.S. Gov't, Non-P.H.S. 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
38
FDA Federal Register documents
13
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
101

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 101 dated records

Research hub

Explore the Desmopressin evidence record

Open all 101 records →
101Dated records
3Evidence types
101Cited public sources
29Source years

Change ledger

Recently changed for Desmopressin

Open all 101 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00223717

PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin.

PeptideScanner change date
November 16, 2026
Cited source date
October 13, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00230594

PeptideScanner retained ClinicalTrials.gov record NCT00230594 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was desmopressin.

PeptideScanner change date
November 16, 2026
Cited source date
May 19, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00902265

PeptideScanner retained ClinicalTrials.gov record NCT00902265 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was desmopressin.

PeptideScanner change date
November 16, 2026
Cited source date
April 19, 2011
Evidence lane
Clinical trials

Official-source collections

Source records for Desmopressin

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis.Neurocritical care · 2026 10 12
  2. Desmopressin for nocturnal enuresis in children.The Cochrane database of systematic reviews · 2025 07 29
  3. Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.Haematologica · 2025 04 03
Explore all selected literature →
ClinicalTrials.gov25

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06020495Registry update October 30, 2026 · current at observation
  2. NCT06635629Registry update August 31, 2026 · current at observation
  3. NCT06337838Registry update May 22, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA38

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA219981Full FDA chronology · original submission status AP 2026-02-27
  2. NDA219873Full FDA chronology · original submission status AP 2026-02-25
  3. ANDA213095Full FDA chronology · original submission status AP 2024-03-21
  4. ANDA216904Full FDA chronology · original submission status AP 2023-03-20
  5. ANDA216922Full FDA chronology · original submission status AP 2022-11-16
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Desmopressin →

Evidence types

Coverage by source year

Selected records span February 21, 1978 to October 30, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine4
  • U.S. Food and Drug Administration5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 101

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06020495↗

    PeptideScanner retained ClinicalTrials.gov record NCT06020495 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  2. Literature metadata

    Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis.↗

    PubMed lists PMID 35478451 in Reviews in endocrine & metabolic disorders as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2022-04-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis.↗

    PubMed lists PMID 42864513 in Neurocritical care as Journal Article, Review, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.↗

    PubMed lists PMID 35199198 in European journal of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2022-02-23 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Desmopressin for nocturnal enuresis in children.↗

    PubMed lists PMID 40728007 in The Cochrane database of systematic reviews as Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06635629↗

    PeptideScanner retained ClinicalTrials.gov record NCT06635629 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  7. Literature metadata

    Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.↗

    PubMed lists PMID 40176766 in Haematologica as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-04-03 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT06337838↗

    PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  9. Regulatory

    Drugs@FDA application ANDA219981↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 219981 with status AP dated 2026-02-27, and names desmopressin acetate among the application record's active ingredients.↗

  10. Regulatory

    Drugs@FDA application NDA219873↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 219873 with status AP dated 2026-02-25, and names desmopressin acetate among the application record's active ingredients.↗

  11. Literature metadata

    Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis.↗

    PubMed lists PMID 27343233 in Pediatrics as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-06-24 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Desmopressin for treating nocturia in men.↗

    PubMed lists PMID 29055129 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S., Systematic Review, with publication-date metadata of 2017-10-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT01223937 · retained source version 2015-10-15:c9d6c8d5c060ce79a820cc99421a4ffb18c74120e4c906015802c4132a162350 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT06020495 · retained source version 2026-10-30:9fb3c53ae1b8a5e92d12b71dfd42d7d2438d0c7633bb7cf029eea75d9a7ca23b ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    ClinicalTrials.gov record NCT06337838 · retained source version 2026-05-22:6c3e4b143f27bd5109df3cc188f6a70d0d091cc5b1118afd1b625216766ae132 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  4. 4
    DDAVP (desmopressin acetate) tablet · SPL version 7 · published 2025-12-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  5. 5
    Drugs@FDA: DDAVP (desmopressin acetate), NDA 019955 · original approval September 6, 1995 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026